公开(公告)号：US20230212231A1

公开(公告)日：2023-07-06

申请号：US17927804

申请日：2021-05-26

申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Baylor Research Institute ,  Assistance Publique - Hopitaux de Paris (APHP) ,  Universite Paris Est Creteil Val de Marne

发明人： Yves LEVY ,  Gérard ZURAWSKI ,  Sandra ZURAWSKI ,  Christine LACABARATZ ,  Sylvain CARDINAUD ,  Mathieu SURENAUD

IPC分类号： C07K14/005 ,  C07K16/28 ,  A61P31/14

CPC分类号： C07K14/005 ,  C07K16/2878 ,  C07K16/2851 ,  A61P31/14 ,  C12N2770/20022 ,  C07K2319/74 ,  C12N2770/20034 ,  A61K39/00

摘要： The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.

公开(公告)号：US20240010739A1

公开(公告)日：2024-01-11

申请号：US18036237

申请日：2021-11-10

申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Assistance Publique - Hopitaux de Paris (APHP) ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne

发明人： Yves LEVY ,  Gérard ZURAWSKI ,  Mireille CENTLIVRE ,  Sandra ZURAWSKI ,  Véronique GODOT

IPC分类号： C07K16/28 ,  C12N15/63

CPC分类号： C07K16/2875 ,  C07K16/2851 ,  C12N15/63 ,  C07K2317/24 ,  C07K2317/565 ,  A61K2039/505

摘要： SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells. The present invention thus relates to antibodies that are directed against a surface antigen of an antigen presenting cell wherein the heavy chain and/or the light chain is conjugated or fused to the receptor-binding domain of the Sars-Cov-2 spike protein

公开(公告)号：US20240131138A1

公开(公告)日：2024-04-25

申请号：US18269113

申请日：2021-12-22

申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Assistance Publique - Hopitaux de Paris ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne

发明人： Yves LEVY ,  Sylvain CARDINAUD ,  Mireille CENTLIVRE ,  Lydie DIEUDONNE ,  Sandra ZURAWSKI ,  Gérard ZURAWSKI

IPC分类号： A61K39/118 ,  A61P31/04 ,  C07K14/295 ,  C07K16/28

CPC分类号： A61K39/118 ,  A61P31/04 ,  C07K14/295 ,  C07K16/2851 ,  C07K16/2878 ,  A61K2039/505

摘要： Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.

公开(公告)号：US20240124532A1

公开(公告)日：2024-04-18

申请号：US18274848

申请日：2022-01-28

申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Assistance Publique - Hopitaux de Paris ,  Universite Paris Est Creteil Val De Marne ,  Baylor Research Institute

发明人： Yves LEVY ,  Sandra ZURAWSKI ,  Gérard ZURAWSKI ,  Mireille CENTLIVRE ,  Lydie DIEUDONNE ,  Sylvain CARDINAUD

IPC分类号： C07K14/295 ,  A61K39/118 ,  C07K16/28

CPC分类号： C07K14/295 ,  A61K39/118 ,  C07K16/2878 ,  C07K2319/33 ,  C07K2319/40

摘要： Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.

公开(公告)号：US20230183366A1

公开(公告)日：2023-06-15

申请号：US17998611

申请日：2021-05-11

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCH MÉDICALE) ,  UNIVERSITE PARIS EST CRETEIL VAL DE MARNE ,  BAYLOR RESEARCH INSTITUTE ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

发明人： Yves LEVY ,  Sandra ZURAWSKI ,  Gérard ZURAWSKI

IPC分类号： C07K16/28 ,  A61P35/00

CPC分类号： C07K16/2878 ,  A61P35/00 ,  C07K2317/565

摘要： The disclosure relates to the field of OX40 activating proteins. More specifically, it is disclosed herein recombinant proteins with OX40 agonist antibodies or their antigen-binding fragments fused or linked to OX40 ligand. Also disclosed is the advantageous use of such OX40 activating proteins, in particular for inducing immune responses directed to delivered antigens such as viral or cancer antigens, and/or for treating cancer.